Answer
Dupilumab inhibits IL-4 signalling via the Type I receptor complex (IL-4Rα/γc) and both IL-4 and IL-13 signalling through the Type II receptor complex (IL-4Rα/IL-13Rα).
Sources for this answer
- Dupixent 300 mg solution for injection in pre-filled syringeSANOFI · emc · SmPC §5.1 Pharmacodynamic properties · Version 27Document updated
Sources checked